News

As part of the €465m deal, Boehringer will start clinical investigation of CV9202 in at least two different lung cancer settings, in combination with afatinib in patients with

The two firms will jointly discover and develop multiple ADCs, antibodies linked to cytotoxic drugs for more targeted delivery, using Sutro’s cell-free protein synthesis platforms Xpress CF and

The Phase III trial is designed to assess the efficacy and safety of plazomicin compared to colistin in patients with bloodstream infections and nosocomial pneumonia caused by carbapenem-resistant

All dosing in the drisapersen clinical program had been placed on hold by GSK on September 20, 2013, upon announcement of the DEMAND III study results. The re-dosing

The Phase 3 clinical trial is designed to demonstrate the superiority, in terms of mortality at 28 days, of a plazomicin-based regimen compared with a colistin-based regimen in

The partnership establishes a major dystonia research prize to expand public awareness, acknowledge key scientific discoveries and incentivize the work of dedicated researchers in dystonia, an under-funded movement

The company will be developing an advanced, automated prototype system for human tissue immuno-oncology profiling, which it will deploy at two leading medical institutions over the course of

MGB-BP-3 is the first antibacterial for over a decade with a novel mode of action from a truly novel class to be developed globally. Funding of £2.7m has

The deal will see Sanofi provide about $200m in equity investments, milestone payments and research and development services over the next four years. Sanofi has already paid MyoKardia